Benefits
Prostate Health
Saw palmetto is one of the most popular supplements for the urinary symptoms of benign prostatic hyperplasia (BPH), but the best evidence is negative. The two largest independent randomized trials, STEP (225 men, 2006) and CAMUS (369 men, dose-escalated to 960 mg/day, 2011), found no benefit over placebo on symptom scores or urine flow. The current Cochrane review (2023, 27 studies) concluded with high-certainty evidence that saw palmetto alone gives little to no improvement in BPH symptoms, quality of life, or flow. The one exception is a specific branded hexanic extract (Permixon), which has positive but industry-funded data and European guideline recognition, and is not the same product as generic saw palmetto capsules.
Urinary Tract Function
Lower urinary tract symptoms (LUTS) are the outcome most studied with saw palmetto, and the largest, most rigorous trials show no improvement in urine flow or symptom scores over placebo. Some smaller and industry-funded trials, and the branded hexanic extract, report modest gains, so results are mixed to negative overall. There is no good evidence for urinary benefit in women.
Hair Growth
The oral human evidence for hair loss is very limited: one small placebo-controlled pilot (about 19 men) tested saw palmetto combined with beta-sitosterol rather than saw palmetto alone, and one open-label study in men found roughly 38 percent responded, fewer than with finasteride. There are no controlled oral trials in women. Minoxidil and finasteride have far stronger evidence for androgenetic alopecia. Take reports of improved hair density as preliminary.
Hormonal Balance
Saw palmetto is often said to affect androgen levels, but this has not been demonstrated in people at supplement doses. Large trials that tracked prostate-specific antigen (a DHT-sensitive marker) found no change, which argues against a meaningful hormonal effect. There are no human trials showing benefit for PCOS or acne.
Anti-Inflammatory Effects
Anti-inflammatory activity has been observed only in laboratory and animal work. No human trial has shown that saw palmetto reduces prostate inflammation or any inflammatory condition.
Mechanism of action
Inhibition of 5-Alpha-Reductase
Saw palmetto inhibits the enzyme 5-alpha-reductase (types 1 and 2), which converts testosterone to dihydrotestosterone (DHT). This 5-alpha-reductase effect is seen mainly in laboratory studies. In people, saw palmetto at usual doses did not lower prostate-specific antigen (a DHT-sensitive marker) in large trials, so any DHT-lowering in the body appears small, and the expected clinical benefits for BPH and hair loss were not confirmed in the best trials.
Anti-Androgenic Effects
Saw palmetto may compete with DHT for binding to androgen receptors, reducing DHT’s activity in tissues like the prostate and scalp. This could help manage symptoms of BPH and hormone-related conditions, though evidence is limited.
Anti-Inflammatory Activity
Its fatty acids and sterols (e.g., beta-sitosterol) exhibit anti-inflammatory properties by inhibiting cyclooxygenase (COX) and lipoxygenase (LOX) pathways, reducing pro-inflammatory mediators like prostaglandins and leukotrienes. This may decrease prostate inflammation and urinary symptoms in BPH.
Estrogenic Effects
Some studies suggest saw palmetto may have mild estrogenic activity, potentially influencing hormone balance, though this mechanism is poorly understood and not consistently supported.
Smooth Muscle Relaxation
Saw palmetto may inhibit alpha-1 adrenergic receptors or reduce calcium influx in smooth muscle cells, promoting relaxation of the bladder and urethra. This could improve urinary flow and reduce lower urinary tract symptoms (LUTS) in BPH.
Apoptosis and Cell Proliferation Inhibition
Preclinical studies indicate saw palmetto may induce apoptosis (programmed cell death) and inhibit proliferation of prostate cells, potentially limiting prostate growth, though human data is sparse.
Clinical trials
Cochrane systematic review of Serenoa repens for lower urinary tract symptoms in BPH: the 2012 version pooled 32 randomized trials (5,666 men), and the 2023 update (27 studies, 4,656 men) reaffirmed the finding using high-certainty evidence.
Pooled across 32 clinical trials.
Primary endpoint negative: saw palmetto did not meaningfully improve urinary symptoms or flow measures vs placebo. Critical: this is a Cochrane-level negative conclusion. The earlier positive trials (mostly small, industry-funded) did not survive rigorous meta-analytic scrutiny. The 'saw palmetto for BPH' marketing is contradicted by best available evidence.
Systematic review and meta-analysis (BJU Int, 2018) of the hexanic extract of Serenoa repens (Permixon, 320 mg/day) for LUTS/BPH, pooling randomized and observational studies. Authored by Spanish urologists with a co-author from the manufacturer, Pierre Fabre.
Pooled trial and observational populations (industry-funded meta-analysis).
Reports modest improvement in symptom score (IPSS) and peak urine flow, but with significant methodological heterogeneity and industry funding. Permixon is the most-studied saw palmetto extract and is recognized in European guidelines, but it is a specific hexanic product, not the same as generic saw palmetto. The two large independent trials, STEP (2006, NEJM) and CAMUS (2011, JAMA), were both negative.
Small double-blind, placebo-controlled pilot (2002) in about 19 men with mild-to-moderate androgenetic alopecia, testing an oral botanical blend of saw palmetto plus beta-sitosterol (not saw palmetto alone) over roughly 5 months.
About 19 men (small pilot).
A majority of the men on the saw palmetto plus beta-sitosterol blend were rated improved versus placebo, but the trial was tiny and tested a combination product, so it cannot show what saw palmetto alone does. Minoxidil and finasteride have far stronger evidence for androgenetic alopecia.
PERMAL trial (2002): 1-year double-blind randomized study in 704 men with BPH (IPSS 10 or more) comparing the hexanic Serenoa repens extract Permixon (320 mg/day) with tamsulosin (0.4 mg/day). No placebo arm. Manufacturer-linked (Pierre Fabre).
704 men with symptomatic BPH.
Symptom scores fell by about 4.4 points in both groups with no significant difference, which the authors read as equivalence. Because there was no placebo arm, part of that improvement likely reflects placebo response and regression to the mean rather than a true drug effect.
A search of PubMed found no controlled oral saw palmetto trial in women with androgenetic alopecia. The main published saw palmetto hair study (2016, Australas J Dermatol) used a topical lotion in 50 men, which is the wrong route for an oral supplement and was not done in women.
No controlled oral trial in women.
There is no controlled oral evidence for saw palmetto in female hair loss. Standard care for female pattern hair loss is topical minoxidil, with spironolactone and other options as needed.